In a June 10, 2021 research note, H.C. Wainwright & Co. analyst Joseph Pantginis provided an update on Targovax ASA's (TRVX:OSE) lead immune activator ONCOS-102, a genetically modified oncolytic adenovirus, it is assessing in several indications.
Regarding ONCOS-102 in malignant pleural mesothelioma, the biotech just announced the median overall survival at 24 months demonstrated in its Phase 1/2 study, and according to Pantginis, the result "provides the rationale for moving the asset to late stage development" in this tumor type.
This open-label study, the analyst reiterated, is testing ONCOS-102 in combination with standard of care pemetrexed/cisplatin as a firstline treatment in malignant pleural mesothelioma. Of the 31 enrolled patients, 20 received the combination treatment whereas the other 11 only received chemotherapy.
In the randomized group of eight patients, median overall survival was between 21.9 and 25 months. The same metric was lower, 13.5 months and 12–16 months, respectively, in the study's chemotherapy-only cohort and historically in patients treated per standard of care.
"Importantly, positive tumor responses and survival outcome were associated with evidence of broad and powerful immune activation assessed in tumor biopsies pre- and post-ONCOS-102 treatment (day 36)," Pantginis pointed out. Patients who received combination treatment, when compared to those who only got the standard of care treatment, demonstrated increased T-cell infiltration and a "shift towards pro-inflammatory immune cells."
Now, Pantginis relayed, Targovax is working to determine the best approach to advance ONCOS-102 in malignant pleural mesothelioma, including the next study's design, scope and timelines. In doing so, the company is talking with key opinion leaders and considering the change taking place in the current malignant pleural mesothelioma treatment landscape. Now, following approval by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency, the combination of ipilimumab and nivolumab is replacing pemetrexed/cisplatin as the firstline standard of care.
In addition, ONCOS-102, in combination with Keytruda, was shown in a recent study to reactivate cyclin kinase inhibitor (CKI)-resistant refractory melanoma. Thus, Targovax is looking at the potential for ONCOS-102 in CKI-resistant malignant pleural mesothelioma as well, "expanding on the demonstrated ability of ONCOS-102 to bring benefit to the majority of patients who still progress after checkpoint inhibitor treatment," Pantginis wrote.
As for ONCOS-102 in PD-1 refractory melanoma, Targovax is currently finalizing the design of a registrational, open-label trial of combination ONCOS-102 and Keytruda. Targovax expects to meet with the FDA in August 2021 and potentially dose the first patient in the second half of 2022.
"Recall that a Phase 2 study, with a single arm with a target population of approximately 100 patients, is expected to be sufficient to seek accelerated approval (with parallel confirmatory trial) and registration," Pantginis wrote. Most likely, Targovax will not have to conduct a randomized trial.
In terms of ONCOS-102 plus Keytruda for melanoma, Targovax recently announced updated immune response data. They showed that ONCOS-102 induced a "broad and powerful" immune response in that T cells in the tumor increased, even in patients whose cancer previously was refractory to the oncolytic virus therapy, T-VEC.
"We believe these data continue to build confidence in ONCOS-102's median overall survival and in its development potential in melanoma and beyond," wrote Pantginis.
Pantginis also addressed Targovax's pipeline. He indicated that ONCOS-102 in melanoma and mesothelioma comprises the bulk of H.C. Wainwright's valuation on Targovax but that the immuno-oncology company is also pursuing novel assets alone or via a collaborative partnership. They include ONCOS-211, a next generation ONCOS, with Leidos; ONCOS plus target tyrosine kinase Inhibition, with Papyrus Therapeutic; and ONCOS in combination with TG-mutant RAS peptides, with Valo Therapeutics.
H.C. Wainwright has a rating of Buy and a price target of NOK17 per share on Targovax. In comparison, its current share price is NOK8.68.
[NLINSERT]
Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
Disclosures from H. C. Wainwright, Targovax ASA, Company Update, June 10, 2021
Investment Banking Services include, but are not limited to, acting as a manager/co-manager in the underwriting or placement of securities, acting as financial advisor, and/or providing corporate finance or capital markets-related services to a company or one of its affiliates or subsidiaries within the past 12 months.
I, Joseph Pantginis, Ph.D. and Emanuela Branchetti, Ph.D., certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.
None of the research analysts or the research analyst's household has a financial interest in the securities of Targovax ASA (including, without limitation, any option, right, warrant, future, long or short position).
As of May 31, 2021 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Targovax ASA.
Neither the research analyst nor the Firm has any material conflict of interest in of which the research analyst knows or has reason to know at the time of publication of this research report.
The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services.
The firm or its affiliates received compensation from Targovax ASA for non-investment banking services in the previous 12 months.
The Firm or its affiliates did not receive compensation from Targovax ASA for investment banking services within twelve months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.
The Firm does not make a market in Targovax ASA as of the date of this research report.
H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report.
